Cannabics Pharmaceuticals Inc. (CNBX) Starts Presentation at 9th Annual LD Micro Invitational
Cannabics Pharmaceuticals (OTC: CNBX) is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient's profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer. For more information, visit the company’s website at www.cannabics.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access…







